Suppr超能文献

基于生理学的改良型口服缓控释制剂的体内外相关性:以米拉贝隆为例的非线 性肠道吸收研究。

Physiologically based in vitro - in vivo correlation of modified release oral formulations with non-linear intestinal absorption: A case study using mirabegron.

机构信息

Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.

Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.

出版信息

Eur J Pharm Biopharm. 2024 Nov;204:114479. doi: 10.1016/j.ejpb.2024.114479. Epub 2024 Sep 2.

Abstract

Establishing an in vitro - in vivo correlation (IVIVC) for oral modified release (MR) formulations would make it possible to substitute an in vitro dissolution test for human bioequivalence (BE) studies when changing the formulation or manufacturing methods. However, the number of IVIVC applications and approvals are reportedly low. One of the main reasons for failure to obtain IVIVCs using conventional methodologies may be the lack of consideration of the dissolution and absorption mechanisms of drugs in the physiological environment. In particular, it is difficult to obtain IVIVC using conventional methodologies for drugs with non-linear absorption processes. Therefore, the aim of the present study was to develop a physiologically based biopharmaceutics model (PBBM) that enables Level A IVIVCs for mirabegron MR formulations with non-linear absorption characteristics. Using human pharmacokinetic (PK) data for immediate-release formulations of mirabegron, the luminal drug concentration-dependent membrane permeation coefficient was calculated through curve fitting. The membrane permeation coefficient data were then applied to the human PK data of the MR formulations to estimate the in vivo dissolution rate by curve fitting. It was assumed that in vivo dissolution could be described using a zero-order rate equation. Furthermore, a Levy plot was generated using the estimated in vivo dissolution rate and the in vitro dissolution rate obtained from the literature. Finally, the dissolution rate of the MR formulations from the Levy plot was applied to the PBBM to predict the oral PK of the mirabegron MR formulations. This PB-IVIVC approach successfully generated linear Levy plots with slopes of almost 1.0 for MR formulations with different dose strengths and dissolution rates. The Cmax values of the MR formulations were accurately predicted using this approach, whereas the prediction errors for AUC exceeded the Level A IVIVC criteria. This can be attributed to the incomplete description of colonic absorption in the current PBBM.

摘要

建立口服改剂型(MR)制剂的体外-体内相关性(IVIVC),可以在改变制剂或生产工艺时,用体外溶出度试验替代人体生物等效性(BE)研究。然而,据报道,IVIVC 的应用和批准数量很少。未能使用常规方法获得 IVIVC 的一个主要原因可能是缺乏对药物在生理环境中的溶解和吸收机制的考虑。特别是,对于具有非线性吸收过程的药物,使用常规方法很难获得 IVIVC。因此,本研究旨在开发一种基于生理学的生物药剂学模型(PBBM),该模型能够对具有非线性吸收特征的米拉贝隆 MR 制剂进行 A 级 IVIVC。使用米拉贝隆即时释放制剂的人体药代动力学(PK)数据,通过曲线拟合计算腔内药物浓度依赖性膜渗透系数。然后将膜渗透系数数据应用于 MR 制剂的人体 PK 数据,通过曲线拟合估计体内溶出率。假设体内溶出可以用零级速率方程来描述。此外,使用从文献中获得的估计的体内溶出率和体外溶出率生成 Levy 图。最后,将从 Levy 图获得的 MR 制剂的溶出速率应用于 PBBM 来预测米拉贝隆 MR 制剂的口服 PK。这种 PB-IVIVC 方法成功地为具有不同剂量强度和溶出率的 MR 制剂生成了线性 Levy 图,斜率几乎为 1.0。使用该方法可以准确预测 MR 制剂的 Cmax 值,而 AUC 的预测误差超过了 A 级 IVIVC 标准。这可以归因于当前 PBBM 中对结肠吸收的不完全描述。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验